These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 8587457)

  • 1. Exercise increases endothelin-1 plasma concentrations in patients with coronary artery disease: modulatory role of LDL cholesterol and of pentaerithrityltetranitrate.
    Predel HG; Knigge H; Prinz U; Kramer HJ; Stalleicken D; Rost RE
    J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S497-501. PubMed ID: 8587457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The exercise-induced increase in plasma levels of endothelin-1 is enhanced in patients with atherosclerotic coronary artery disease. Modulation by pentaerithrityltetranitrat (PETN).
    Predel HG; Knigge H; Prinz U; Stalleicken D; Kramer HJ; Rost RE
    Agents Actions Suppl; 1995; 45():219-25. PubMed ID: 7717184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Endothelin and big endothelin in coronary heart disease and acute coronary syndromes].
    Borries M; Heins M; Fischer Y; Stiegler H; Schoebel FC; Reinauer H; Strauer BE; Leschke M
    Z Kardiol; 1996 Oct; 85(10):761-7. PubMed ID: 9036701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Helicobacter pylori (H. pylori) infection in coronary artery disease: influence of H. pylori eradication on coronary artery lumen after percutaneous transluminal coronary angioplasty. The detection of H. pylori specific DNA in human coronary atherosclerotic plaque.
    Kowalski M
    J Physiol Pharmacol; 2001 Aug; 52(1 Suppl 1):3-31. PubMed ID: 11795863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of trimetazidine on heart rate variability in patients with slow coronary artery flow.
    Topal E; Ozdemir R; Barutcu I; Aksoy Y; Sincer I; Akturk E; Cehreli S
    J Electrocardiol; 2006 Apr; 39(2):211-8. PubMed ID: 16580422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical evaluation of pentaerythritol tetranitrate in two doses in patients with stable angina pectoris].
    Kośmicki MA; Malczewska B; Sadowski Z
    Przegl Lek; 2005; 62(1):8-12. PubMed ID: 16053212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The nitric oxide donor pentaerythritol tetranitrate can preserve endothelial function in established atherosclerosis.
    Hacker A; Müller S; Meyer W; Kojda G
    Br J Pharmacol; 2001 Apr; 132(8):1707-14. PubMed ID: 11309242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma HDL-cholesterol has an effect on nitric oxide production and arachidonic acid metabolism in the platelet membranes of coronary heart disease patients without LDL-hypercholesterolemia.
    Tretjakovs P; Kalnins U; Dabina I; Dinne I; Erglis A; Kumsars I; Jurka A
    Med Sci Monit; 2000; 6(3):507-11. PubMed ID: 11208362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Tumor necrosis factor alpha and its soluble receptors in serum of patients with coronary artery disease].
    Mizia-Stec K; Mandecki T; Zahorska-Markiewicz B; Janowska J; Szulc A; Jastrzebska-Maj E; Szymański L
    Pol Merkur Lekarski; 2001 Jul; 11(61):19-25. PubMed ID: 11579824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of a 4-week treatment with prostaglandin E1 on plasma endothelin-1 release in patients with intermittent claudication.
    Mangiafico RA; Malatino LS; Santonocito M; Messina R; Attinà T; Dell'Arte S; Sarnataro F
    Int J Clin Pharmacol Ther; 1999 Jul; 37(7):347-51. PubMed ID: 10442509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of different doses of atorvastatin on plasma endothelin-1 levels in type 2 diabetic patients with dyslipidemia.
    Lam HC; Chu CH; Wei MC; Keng HM; Lu CC; Sun CC; Lee JK; Chuang MJ; Wang MC; Tai MH
    Exp Biol Med (Maywood); 2006 Jun; 231(6):1010-5. PubMed ID: 16741040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma endothelin-1 levels after exercise in patients with congenital heart disease.
    Ishikawa S; Miyauchi T; Sakai S; Sunagawa H; Honda S; Maeda S; Matsuda M; Yamaguchi I; Goto K; Sugishita Y
    J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S491-3. PubMed ID: 8587455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic factors clustering, lipoprotein cholesterol, apolipoprotein B, lipoprotein (a) and apolipoprotein E phenotypes in premature coronary artery disease in French Canadians.
    Weber M; McNicoll S; Marcil M; Connelly P; Lussier-Cacan S; Davignon J; Latour Y; Genest J
    Can J Cardiol; 1997 Mar; 13(3):253-60. PubMed ID: 9117913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of pentaerithrityl-tetranitrate on parameters of the microcirculation.
    Böhm C; Haustein KO
    Int J Clin Pharmacol Ther; 1998 Jul; 36(7):398-402. PubMed ID: 9707356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial).
    Goldenberg I; Benderly M; Sidi R; Boyko V; Tenenbaum A; Tanne D; Behar S
    Am J Cardiol; 2009 Jan; 103(1):41-5. PubMed ID: 19101227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
    Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
    Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel atherogenesis markers for identification of patients with a multivessel coronary artery disease.
    Krecki R; Drozdz J; Szcześniak P; Orszulak-Michalak D; Krzemińska-Pakuła M
    Kardiol Pol; 2008 Nov; 66(11):1173-80; discussion 1181-2. PubMed ID: 19105094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significantly higher levels of oxidized LDL autoantibody in coronary artery disease patients.
    Liang KW; Huang JL; Kao CH; Hsueh CW; Ho HY; Lee WL; Wang KY; Huang DS; Chen YT; Ting CT
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Feb; 63(2):101-6. PubMed ID: 10677919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical trial of an educational intervention to achieve recommended cholesterol levels in patients with coronary artery disease.
    Lichtman JH; Amatruda J; Yaari S; Cheng S; Smith GL; Mattera JA; Roumanis SA; Wang Y; Radford MJ; Krumholz HM
    Am Heart J; 2004 Mar; 147(3):522-8. PubMed ID: 14999204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relationship of TFPI, Lp(a), and oxidized LDL antibody levels in patients with coronary artery disease.
    Bilgen D; Sönmez H; Ekmekçi H; Ulutin T; Oztürk Z; Kökoğlu E; Bayram C; Soner A; Domaniç N
    Clin Biochem; 2005 Jan; 38(1):92-6. PubMed ID: 15607324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.